Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew N Phillips

Showing results (61-70 of 287) with videos related to

Pageof 29
Sort By:
Antiviral Therapy|November 30, 2005
Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection?Amanda Mocroft, Jurgen Rockstroh, Vincent Soriano, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|December 20, 2019
Plasma Albumin and Incident Cardiovascular Disease: Results From the CGPS and an Updated Meta-AnalysisAndreas Ronit, Ditte M Kirkegaard-Klitbo, Tine L Dohlmann, et al.
AIDS (London, England)|April 16, 2002
CD4 cell count changes in individuals with counts above 500 cells/mm and viral loads below 50 copies/ml on antiretroviral therapyAndrew N Phillips, Michael Youle, Fiona Lampe, et al.
AIDS (London, England)|August 19, 2004
Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppressionAndrew N Phillips, Bruno Ledergerber, Andrezej Horban, et al.
AIDS (London, England)|April 2, 2019
Risk factors for antiretroviral therapy (ART) discontinuation in a large multinational trial of early ART initiatorsLoveleen Bansi-Matharu, Gabriela Rodriguez Loria, Stephen R Cole, et al.
Plos One|April 23, 2015
Projected Lifetime Healthcare Costs Associated with HIV InfectionFumiyo Nakagawa, Alec Miners, Colette J Smith, et al.
AIDS (London, England)|March 21, 2003
Viral breakthrough after suppression with highly active antiretroviral therapy: experience from 233 individuals with viral loads of less than 50 copies/ml followed for up to 4 yearsFiona C Lampe, Margaret A Johnson, Marc Lipman, et al.
AIDS (London, England)|August 2, 2003
Virological rebound after suppression on highly active antiretroviral therapyAmanda Mocroft, Lidia Ruiz, Peter Reiss, et al.
Antiviral Therapy|August 6, 2011
Predictors of having a resistance test following confirmed virological failure of combination antiretroviral therapy: data from EuroSIDAZoe V Fox, Alessandro Cozzi-Lepri, Antonella D'Arminio Monforte, et al.
The Journal of Infectious Diseases|July 23, 2002
Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell countsVeronica Miller, Andrew N Phillips, Bonaventura Clotet, et al.
Pageof 29

Showing results (61-70 of 287) with videos related to

Sort By:
Pageof 29
Antiviral Therapy|November 30, 2005
Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection?Amanda Mocroft, Jurgen Rockstroh, Vincent Soriano, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|December 20, 2019
Plasma Albumin and Incident Cardiovascular Disease: Results From the CGPS and an Updated Meta-AnalysisAndreas Ronit, Ditte M Kirkegaard-Klitbo, Tine L Dohlmann, et al.
AIDS (London, England)|April 16, 2002
CD4 cell count changes in individuals with counts above 500 cells/mm and viral loads below 50 copies/ml on antiretroviral therapyAndrew N Phillips, Michael Youle, Fiona Lampe, et al.
AIDS (London, England)|August 19, 2004
Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppressionAndrew N Phillips, Bruno Ledergerber, Andrezej Horban, et al.
AIDS (London, England)|April 2, 2019
Risk factors for antiretroviral therapy (ART) discontinuation in a large multinational trial of early ART initiatorsLoveleen Bansi-Matharu, Gabriela Rodriguez Loria, Stephen R Cole, et al.
Plos One|April 23, 2015
Projected Lifetime Healthcare Costs Associated with HIV InfectionFumiyo Nakagawa, Alec Miners, Colette J Smith, et al.
AIDS (London, England)|March 21, 2003
Viral breakthrough after suppression with highly active antiretroviral therapy: experience from 233 individuals with viral loads of less than 50 copies/ml followed for up to 4 yearsFiona C Lampe, Margaret A Johnson, Marc Lipman, et al.
AIDS (London, England)|August 2, 2003
Virological rebound after suppression on highly active antiretroviral therapyAmanda Mocroft, Lidia Ruiz, Peter Reiss, et al.
Antiviral Therapy|August 6, 2011
Predictors of having a resistance test following confirmed virological failure of combination antiretroviral therapy: data from EuroSIDAZoe V Fox, Alessandro Cozzi-Lepri, Antonella D'Arminio Monforte, et al.
The Journal of Infectious Diseases|July 23, 2002
Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell countsVeronica Miller, Andrew N Phillips, Bonaventura Clotet, et al.
Pageof 29